Bio-Rad Laboratories (Bio-Rad Laboratories) Debt-to-Equity : 0.16 (As of Dec. 2023)

View and export this data going back to 1980. Start your Free Trial

What is Bio-Rad Laboratories Debt-to-Equity?

Bio-Rad Laboratories's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $41 Mil. Bio-Rad Laboratories's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $1,365 Mil. Bio-Rad Laboratories's Total Stockholders Equity for the quarter that ended in Dec. 2023 was $8,741 Mil. Bio-Rad Laboratories's debt to equity for the quarter that ended in Dec. 2023 was 0.16.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Bio-Rad Laboratories's Debt-to-Equity or its related term are showing as below:

BIO' s Debt-to-Equity Range Over the Past 10 Years
Min: 0.02 Med: 0.15 Max: 0.2
Current: 0.16

During the past 13 years, the highest Debt-to-Equity Ratio of Bio-Rad Laboratories was 0.20. The lowest was 0.02. And the median was 0.15.

BIO's Debt-to-Equity is ranked better than
56.1% of 713 companies
in the Medical Devices & Instruments industry
Industry Median: 0.21 vs BIO: 0.16

Bio-Rad Laboratories Debt-to-Equity Historical Data

The historical data trend for Bio-Rad Laboratories's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bio-Rad Laboratories Debt-to-Equity Chart

Bio-Rad Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.11

0.02

0.14

0.16

Bio-Rad Laboratories Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-Equity	Get a 7-Day Free Trial															0.14	0.14	0.16	0.17	0.16

Competitive Comparison of Bio-Rad Laboratories's Debt-to-Equity

For the Medical Devices subindustry, Bio-Rad Laboratories's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bio-Rad Laboratories's Debt-to-Equity Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bio-Rad Laboratories's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Bio-Rad Laboratories's Debt-to-Equity falls into.

Bio-Rad Laboratories Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Bio-Rad Laboratories's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(40.865	+	1364.578)	/	8741.133
	=	0.16

Bio-Rad Laboratories's Debt to Equity Ratio for the quarter that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(40.865	+	1364.578)	/	8741.133
	=	0.16

Bio-Rad Laboratories (NYSE:BIO) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Bio-Rad Laboratories Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Bio-Rad Laboratories's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Bio-Rad Laboratories (Bio-Rad Laboratories) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bio-Rad Laboratories Inc (NYSE:BIO) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

BIO.B:USA BUW:Germany BUWA:Germany

Address

1000 Alfred Nobel Drive, Hercules, CA, USA, 94547

Website

https://www.bio-rad.com

Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas, Europe and Africa , and Asia-Pacific. Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.

Executives

Tania Devilliers	officer: INT PRIN ACCTG OFC	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Sedat Evran	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Corey Colleen	officer: EVP, Global Human Resources	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Diane Dahowski	officer: EVP, Global Supply Chain	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Schwartz Allison	director	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Simon May	officer: EVP, President, LSG	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Andrew J. Last	officer: EVP, Chief Operating Officer	3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051
Ajit Ramalingam	officer: SVP, Chief Accounting Officer	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Ilan Daskal	officer: EVP, Chief Financial Officer	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Timothy S Ernst	officer: EVP, General Counsel & Sec	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Dara Wright	officer: Executive Vice President	C/O BIO-RAD LABORATORIES, INC., 1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Michael Crowley	officer: EVP, GBL Commercial Operations	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Steven D Schwartz	10 percent owner	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547
Alice N Schwartz	director, 10 percent owner
Norman D Schwartz	director, 10 percent owner, officer: Chairman, President, and CEO	1000 ALFRED NOBEL DRIVE, HERCULES CA 94547